Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

Strategies for engaging patients in the digital age

By Laura Meade

- PMLiVE

The MM+M Agency 100 report: Oxford PharmaGenesis is recognized as an industry leader for the third year running

We have scored a hat-trick, with media brand Medical Marketing and Media (MM+M) listing Oxford PharmaGenesis in its Agency 100 report for a third consecutive year.

Oxford PharmaGenesis

- PMLiVE

FDA grants accelerated approval to Sarepta’s Duchenne muscular dystrophy gene therapy

The disease occurs in up to one in every 5,000 newborn males worldwide

- PMLiVE

World Health Organization publishes research agenda for antimicrobial resistance

AMR has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

The approval for the leukaemia drug was supported by additional data from two phase 3 studies

- PMLiVE

Gilead’s chronic hepatitis D antiviral shows long-term efficacy in late-stage trial

Hepatitis D virus is estimated to affect more than 230,000 people in the US and Europe

[Free Whitepaper] 5 Principles for Greater Diversity in Patient Recruitment

Discover how community engagement could enhance diversity in clinical trials patient recruitment

Innovative Trials

- PMLiVE

Innovative Trials attended the Inspire Hertfordshire Award gala dinner

Innovative Trials, a global clinical trial patient recruitment and retention company based in Hertfordshire, has been recognised for its contribution to the county’s economy and business reputation.

Innovative Trials

- PMLiVE

The importance of the patient voice in support programmes

By Sheetal Padania

How the Legally Blind Can Achieve Enhanced Vision

Roland Mattern, Director of Product Marketing at eSight Eyewear, shares how eSight’s technologies are being used to bring sight back to people living with central vision loss. He also discusses...

Impetus Digital

- PMLiVE

Pfizer’s Talzenna combination receives FDA approval for metastatic prostate cancer

Up to 20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

- PMLiVE

bluebird bio’s sickle cell gene therapy accepted for FDA priority review

The genetic disease affects approximately 100,000 people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links